Search Clinical Trials
Sponsor Condition of Interest |
---|
AMX0035 and Progressive Supranuclear Palsy
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy
PSP
Neurodegenerative Diseases
Atypical Parkinsonism
ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with
Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo
controlled phase, followed by an optional open-label extension phase.
expand
ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo controlled phase, followed by an optional open-label extension phase. Type: Interventional Start Date: Dec 2023 |
Tocilizumab in Lung Transplantation
National Institute of Allergy and Infectious Diseases (NIAID)
Lung Transplant
This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to
receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance
immunosuppression or placebo (sterile normal saline) plus standard triple maintenance
immunosuppression... expand
This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids). The primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance immunosuppression plus placebo (saline) as defined by a composite endpoint of a) CLAD, b) listed for re-transplantation, and c) death Type: Interventional Start Date: Feb 2024 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive...
Bristol-Myers Squibb
Progressive Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278
in Participants with Progressive Pulmonary Fibrosis.
expand
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis. Type: Interventional Start Date: Oct 2023 |
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in...
Jazz Pharmaceuticals
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
The purpose of this study is to investigate behavioral and other co-occurring outcomes with
EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis
complex (TSC) who experience seizures.
expand
The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures. Type: Interventional Start Date: Jun 2023 |
Health Outcomes of Parents With Cystic Fibrosis
University of Pittsburgh
Cystic Fibrosis
Parenthood Status
This project will determine the health impact of parenthood on people with cystic fibrosis
(CF). The study team will use retrospective data to provide relatively immediate evidence on
parenthood's effect on pulmonary health.
expand
This project will determine the health impact of parenthood on people with cystic fibrosis (CF). The study team will use retrospective data to provide relatively immediate evidence on parenthood's effect on pulmonary health. Type: Observational Start Date: Jul 2023 |
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
Massachusetts General Hospital
Coronary Artery Disease
The goal of this randomized controlled trial is to assess the impact of disclosing a high
polygenic risk result for coronary artery disease on change in cardiovascular health over one
year.
expand
The goal of this randomized controlled trial is to assess the impact of disclosing a high polygenic risk result for coronary artery disease on change in cardiovascular health over one year. Type: Interventional Start Date: Dec 2023 |
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine,...
Kura Oncology, Inc.
Acute Myeloid Leukemia
Mixed Lineage Acute Leukemia
Mixed Lineage Leukemia Gene Mutation
Mixed Phenotype Acute Leukemia
Refractory AML
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic
activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3
for two different molecularly-defined arms, NPM1-m and KMT2A-r.
expand
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r. Type: Interventional Start Date: Jul 2023 |
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Elicio Therapeutics
Pancreatic Ductal Adenocarcinoma
Colorectal Cancer
KRAS G12D
KRAS G12R
KRAS G12V
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a
lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of
lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects
with... expand
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909. Type: Interventional Start Date: Apr 2023 |
A Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
Small Cell Lung Cancer (SCLC)
Large Cell Neuroendocrine Cancer (LCNEC)
Neuroendocrine Prostate Cancer (NEPC)
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
PT217 is a bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47).
This is an open label, Phase I study to evaluate the safety, tolerability, pharmacokinetics
(PK) and preliminary efficacy of PT217 in subjects with advanced or refractory cancers.... expand
PT217 is a bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47). This is an open label, Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of PT217 in subjects with advanced or refractory cancers. Patients with the following tumor types will be eligible for screening: unresectable small cell lung cancer (SCLC), large cell neuroendocrine cancer (LCNEC), neuroendocrine prostate cancer (NEPC) and gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC). Patients must have progressed after standard therapy (platinum-based chemotherapy) or standard therapy has proven to be ineffective, intolerable or is considered inappropriate. Type: Interventional Start Date: Sep 2023 |
Thoraflex Hybrid and Relay Extension Post-Approval Study
Vascutek Ltd.
Thoracic Diseases
Aortic Aneurysm
Aortic Dissection
Thoracic Aortic Aneurysm
Thoracic Aortic Dissection
The goal of this observational study is to evaluate the Thoraflex Hybrid device alone and in
combination with the RelayPro NBS stent-graft in the treatment of aortic disease affecting
the aortic arch and descending aorta with or without involvement of the ascending aorta.... expand
The goal of this observational study is to evaluate the Thoraflex Hybrid device alone and in combination with the RelayPro NBS stent-graft in the treatment of aortic disease affecting the aortic arch and descending aorta with or without involvement of the ascending aorta. Patients who undergo treatment with the Thoraflex Hybrid device with or without extension with a RelayPro NBS stent-graft will be eligible for enrolment and study activities and follow-up regime will follow standard care at each participating site. Participant involvement in the study will last for a total of 10 years from the point at which the Thoraflex Hybrid device is placed. Type: Observational Start Date: Mar 2023 |
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor...
Hoffmann-La Roche
Small Cell Lung Cancer
Neuroendocrine Carcinoma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789. The study will have 3
parts: Dose Escalation (Parts 1 and 2) and Dose Expansion (Part 3). Participants with
advanced... expand
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789. The study will have 3 parts: Dose Escalation (Parts 1 and 2) and Dose Expansion (Part 3). Participants with advanced stage small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) will be enrolled in the study. Type: Interventional Start Date: Jan 2023 |
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With...
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Cutaneous Melanoma
Carcinoma, Renal Cell
Carcinoma, Ovarian Epithelial
Nasopharyngeal Carcinoma
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115
in combination with pembrolizumab in patients with select advanced cancers, and to identify
the maximum tolerated dose and/or recommended dose.
expand
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose. Type: Interventional Start Date: Oct 2022 |
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Abcuro, Inc.
T-cell Large Granular Lymphocytic Leukemia
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic
Leukemia (T-LGLL)
expand
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL) Type: Interventional Start Date: Sep 2022 |
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company
Breast Neoplasms
The main purpose of this study is to measure how well imlunestrant works compared to standard
hormone therapy in participants with early breast cancer that is estrogen receptor positive
(ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken... expand
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years. Type: Interventional Start Date: Oct 2022 |
Culturally Aware AET Non-Initiation Intervention
Massachusetts General Hospital
Breast Cancer
Survivorship
Treatment Compliance
Treatment Adherence
Treatment Refusal
The purpose of this study is to examine the feasibility and acceptability of a brief,
nurse-led intervention to support breast cancer survivors who have delayed initiation of
hormonal therapy or who have concerns about starting hormonal therapy.
expand
The purpose of this study is to examine the feasibility and acceptability of a brief, nurse-led intervention to support breast cancer survivors who have delayed initiation of hormonal therapy or who have concerns about starting hormonal therapy. Type: Interventional Start Date: Jul 2022 |
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With...
Genentech, Inc.
Systemic Sclerosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)
of RO7303509 treatment in participants with systemic sclerosis (SSc) during a
multiple-ascending-dose (MAD) portion of the trial. In the MAD phase, increasing doses of
study drug will... expand
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of RO7303509 treatment in participants with systemic sclerosis (SSc) during a multiple-ascending-dose (MAD) portion of the trial. In the MAD phase, increasing doses of study drug will be tested sequentially. For each dose tested, the MAD stage will consist of a treatment period of 12 weeks followed by either a safety follow-up period of 13 weeks or continued treatment in an optional open-label safety extension (OSE) stage of 52 weeks to assess the long-term safety. All patients in the OSE stage will receive RO7303509 and no patient will receive placebo. Type: Interventional Start Date: Jan 2023 |
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
ALK-Abelló A/S
Peanut Allergy
This clinical research study investigates the safety and tolerability of a peanut
SLIT-tablet.
expand
This clinical research study investigates the safety and tolerability of a peanut SLIT-tablet. Type: Interventional Start Date: Sep 2022 |
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab...
Gilead Sciences
Triple Negative Breast Cancer
PD-L1 Positive
The primary objective of this study is to compare the progression-free survival (PFS) between
sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice
(TPC) and pembrolizumab in participants with previously untreated, locally advanced
inoperable... expand
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1). Type: Interventional Start Date: Jul 2022 |
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants...
Arcus Biosciences, Inc.
Gastrointestinal Tract Malignancies
The purpose of this study is to evaluate the safety and preliminary clinical activity of
treatment combinations with and without chemotherapy in participants with locally advanced
unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will
consist... expand
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil). Type: Interventional Start Date: Jun 2022 |
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD...
Hansa Biopharma AB
Kidney Transplantation in Highly Sensitized Patients
An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in
highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a
deceased donor, comparing desensitization using imlifidase with standard of care
expand
An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care Type: Interventional Start Date: Oct 2021 |
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is
effective and safe in delaying cancer return in participants with early-stage non-small cell
lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned... expand
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years. Type: Interventional Start Date: Dec 2021 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast...
Hoffmann-La Roche
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants
with breast cancer. Cohort 1 will focus on participants with inoperable, locally advanced or
metastatic, estrogen receptor (ER)-positive, HER2-negative breast cancer who had disease
progression... expand
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor (ER)-positive, HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting. Cohort 2 will focus on inoperable, locally advanced or metastatic, ER-positive, HER2-positive breast cancer with previous progression to standard-of-care anti-HER2 therapies, of which one was a trastuzumab-and-taxane-based systemic therapy (including in the early setting if recurrence occurred within 6 months of finishing adjuvant therapy) and one was a HER2-targeting antibody-drug conjugate (ADC; e.g., ado-trastuzumab emtansine or trastuzumab-deruxtecan) or a HER2-targeting tyrosine kinase inhibitor (TKI; e.g., tucatinib, lapatinib, pyrotinib or neratinib). The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population. During Stage 1, participants in each cohort will be randomly assigned to treatment arms. Participants in the control or experimental arms who experience unacceptable toxicity, disease progression as determined by the investigator according to RECIST v1.1, or loss of clinical benefit as determined by the investigator during Stage 1 will be given the option of receiving a different treatment combination during Stage 2, provided they meet eligibility criteria and a treatment arm is open for enrollment. No Stage 2 treatment is currently available. Type: Interventional Start Date: Jun 2021 |
A Study Comparing Two Types of Supportive Interventions for Caregivers of Patients With Cancer
Memorial Sloan Kettering Cancer Center
Cancer Patients
Family Caregivers
The purpose of this study is to compare two types of therapy for caregivers of cancer
patients: Emotion Regulation Therapy for Cancer Caregivers (ERT-C) and Cognitive Behavioral
Therapy (CBT-C). The researchers want to see if ERT-C is better than, the same as, or worse
than... expand
The purpose of this study is to compare two types of therapy for caregivers of cancer patients: Emotion Regulation Therapy for Cancer Caregivers (ERT-C) and Cognitive Behavioral Therapy (CBT-C). The researchers want to see if ERT-C is better than, the same as, or worse than traditional CBT-C at improving caregiver distress. The researchers will look at how the two types of therapy affect caregivers' anxiety, depression, and quality of life. The researchers will also see how ERT-C and CBT-C affect hormone and stress levels in caregivers' saliva samples. In addition, this trial will enroll cancer patients in this study to see how their caregivers' participation in ERT-C or CBT may affect the patients' quality of life, stress, and use of healthcare services. Participants who become bereaved while on study will be given the option to withdraw or remain on study. Assessments for bereaved caregivers will not include the Caregiver Quality of Life Index-Cancer (CQOLC) or the Caregiver Reaction Assessment (CRA). Type: Interventional Start Date: Feb 2021 |
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Children's Oncology Group
Central Nervous System Nongerminomatous Germ Cell Tumor
Choriocarcinoma
Embryonal Carcinoma
Immature Teratoma
Malignant Teratoma
This phase II trial studies the best approach to combine chemotherapy and radiation therapy
(RT) based on the patient's response to induction chemotherapy in patients with
non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain
or body (localized).... expand
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT. Type: Interventional Start Date: Jul 2021 |
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Massachusetts General Hospital
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
This research study is studying a combination of drugs as a possible treatment for chronic
lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
The names of the study drugs involved in this study are:
- obinutuzumab
- venetoclax
-... expand
This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: - obinutuzumab - venetoclax - acalabrutinib Type: Interventional Start Date: Oct 2020 |
- Previous
- Next